A Single Dose Pharmacokinetics Study of LY2624803 in Subjects With Hepatic Impairment
Latest Information Update: 14 Jan 2020
At a glance
- Drugs LY 2624803 (Primary)
- Indications Insomnia
- Focus Pharmacokinetics
- Sponsors Eli Lilly and Company
Most Recent Events
- 02 Jun 2011 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
- 14 Dec 2010 New trial record